The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)

Radiation therapy (RT)-free pembrolizumab plus chemotherapy (P+C) for PD-L1 TPS ≥50% locally advanced non-small cell lung cancer (LA-NSCLC): Primary analysis from multicenter single arm phase II study (Evolution trial; WJOG11819L).

Akito  Hata

Speakers' Bureau - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Lilly; MSD; Pfizer; Taiho Pharmaceutical

Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Lilly (Inst); MSD (Inst); Taiho Pharmaceutical (Inst)

Taira  Ninomaru

No Relationships to Disclose

Hideaki  Okada

No Relationships to Disclose

Yoshihito  Kogure

Honoraria - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; GlaxoSmithKline; Lilly Japan; MSD; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda

Research Funding - Abbvie (Inst); AstraZeneca (Inst); Chugai Pharma (Inst); Fujifilm (Inst); GlaxoSmithKline (Inst); Janssen (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Sanofi (Inst)

Masahide  Oki

Speakers' Bureau - AMCO; AstraZeneca Japan; Canon Medical System; Fujifilm; Janssen Medical Affairs; Merit Medical Systems; Olympus Medical Systems

Research Funding - Abbvie; AstraZeneca Japan; GlaxoSmithKline K.K.; MSD K.K; PAREXEL; Sanofi

Nobuyuki  Katakami

Speakers' Bureau - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Daiichi Sankyo; Dainippon Sumitomo Pharma; Janssen; Lilly; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical

Research Funding - Abbvie (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Delta-Fly Pharma (Inst); Eisai (Inst); Kyowa Hakko Kirin (Inst); Lilly (Inst); Maruishi Pharma (Inst); Merck Serono (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Shionogi (Inst); Taiho Pharmaceutical (Inst)

Takashi  Kijima

Consulting or Advisory Role - MSD

Research Funding - MSD

Toshihide  Yokoyama

Honoraria - AstraZeneca; Bristol-Myers Squibb Co. Ltd.; Chugai Pharma; Lilly Japan; Merck Biopharma Co. Ltd.; MSD; Nippon Kayaku; Novartis; Ono Pharmaceutical; Pfizer; Takeda

Research Funding - Abbvie (Inst); Abbvie (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb Co. Ltd. (Inst); Chugai Pharma (Inst); Daiichi Sankyo Co. Ltd. (Inst); Delta-Fly Pharma (Inst); Janssen (Inst); MSD K.K (Inst); PAREXEL International Inc. (Inst); Takeda (Inst)

Hirotaka  Matsumoto

Speakers' Bureau - AstraZenecaA; Boehringer Ingelheim; Ono Pharmaceutical

Yuki  Sato

Honoraria - AstraZeneca; Bristol-Myers Squibb Co Ltd; Chugai Pharma; Daiichi Sankyo/Arqule; Kyowa Kirin; Lilly Japan; MSD; Nippon Kayaku; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda

Terufumi  Kato

Employment - Lilly (I)

Honoraria - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Janssen; Lilly; Merck KGaA; Merck Sharp & Dohme; Novartis; Ono Pharmaceutical; Pfizer; Takeda

Consulting or Advisory Role - AstraZeneca; DaiichiSankyo; Janssen; Merck KGaA; MSD; Novartis; Pfizer

Research Funding - Abbvie (Inst); Amgen (Inst); ArriVent Biopharma (Inst); AstraZeneca (Inst); Bayer; BeiGene (Inst); Blueprint Medicines (Inst); Bristol-Myers Squibb Japan (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Haihe Biopharma (Inst); Janssen (Inst); Lilly (Inst); Merck KGaA (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Pfizer (Inst); Regeneron (Inst); Takeda (Inst)

Shunichi  Sugawara

Honoraria - Abbvie; Amgen; AstraZeneca; Bristol-Myers Squibb; Chugai Pharma; Kyowa Kirin; Lilly; Merck; MSD K.K; Nippon Boehringer Ingelheim; Nippon Kayaku; Novartis; Ono Pharmaceutical; Otsuka; Pfizer; Taiho Pharmaceutical; Takeda; Thermo Fisher Scientific; TOWA PHARMACEUTICAL

Research Funding - Abbvie (Inst); Anheart Therapeutics (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); MSD K.K (Inst); Ono Pharmaceutical (Inst)

Takeshi  Sawada

No Relationships to Disclose

Kenichi  Yoshimura

Honoraria - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Eisai; Lilly; Nihon-Shinyaku; Nihonkayaku; Novartis; Otsuka; Pfizer; Taiho Pharmaceutical; Takeda

Consulting or Advisory Role - BrightPath Biotheraputics; Nippon Shinyaku; Sysmex

Takashi  Seto

Employment - Precision Medicine Asia

Honoraria - Amgen; Anheart Therapeutics; AstraZeneca; Bristol-Myers Squibb; Chugai Pharma; GlaxoSmithKline; Lilly Japan; MSD; Novartis; Ono Pharmaceutical; Pfizer; Takeda

Kazuhiko  Nakagawa

Honoraria - AstraZeneca Japan; Bayer Yakuhin; Bristol Myers Squibb Company; Chugai Pharma; Daiichi Sankyo Co., Ltd.; Global Health Consulting Japan Co., Ltd.; Hisamitsu Pharmaceutical; Incyte; Janssen; Lilly Japan; M3; Medical Mobile Communications; Merck; MSD K.K; Nippon Boehringer Ingelheim; Novartis; Ono Pharmaceutical; Otsuka; Pfizer; Taiho Pharmaceutical; The Yomiuri Shimbun; YODOSHA

Consulting or Advisory Role - Lilly Japan; Ono Pharmaceutical

Research Funding - A2 Healyhcare Corp. (Inst); Abbvie (Inst); Amgen (Inst); Ascent Development Services (Inst); Astellas Pharma (Inst); AstraZeneca Japan (Inst); Bayer Yakuhin (Inst); Bristol-Myers Squibb K.K. (Inst); Chugai Pharma (Inst); CMIC CO., Ltd. (Inst); Eisai (Inst); Eisai (Inst); EPS Holdings (Inst); EPS Holdings (Inst); GlaxoSmithKline K.K. (Inst); IQvia (Inst); Janssen (Inst); Japan Clinical Cancer Research Organization (Inst); Kobayashi Pharmaceutical (Inst); Labcorp Drug Development (Inst); MSD K.K (Inst); Nippon Boehringer Ingelheim (Inst); Nippon Kayaku (Inst); Otsuka (Inst); Pfizer (Inst); Pfizer (Inst); PRA HEALTHSCIENCES (Inst); Sanofi (Inst); Shionogi (Inst); SRL Medisearch Inc. (Inst); Syneos Health (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Thoracic Oncology Research Group (Inst)

Isamu  Okamoto

Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Lilly Japan; MSD Oncology; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical

Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo/UCB Japan; Lilly Japan; Ono Pharmaceutical; Pfizer

Research Funding - Abbvie (Inst); Amgen (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Chugai/Roche (Inst); Daiichi Sankyo/UCB Japan (Inst); Lilly (Inst); MSD Oncology (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)

Nobuyuki  Yamamoto

Honoraria - Abbvie; Acuuray; Amgen; AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Daiichi Sankyo; Guardant Health; Janssen; Kyorin; Lilly Japan; Merck; Miyarisan pharmaceutical; MSD; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda; TERUMO; Tsumura & Co.

Consulting or Advisory Role - Amgen; AstraZeneca; Chugai Pharma; Lilly Japan; MSD; Novartis; Ono Pharmaceutical

Research Funding - A2 Healthcare (Inst); Abbvie (Inst); Amgen (Inst); Amgen (Inst); Asahi Kasei (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb Japan (Inst); Chugai Pharma (Inst); EPS Corporation (Inst); IQvia (Inst); Janssen (Inst); Mebix (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)